What can oncologists learn from HIV?

Lancet Oncology

Volumn 4, Issue 7, 2003, Pages 438-445

  Stebbing, Justin ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; BASIC FIBROBLAST GROWTH FACTOR; CYTOTOXIC AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; INDINAVIR; LAMIVUDINE; METHOTREXATE; MONOCLONAL ANTIBODY; NELFINAVIR; NEVIRAPINE; PACLITAXEL; PHENYLALANINE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RITONAVIR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESEARCH; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TARGETING; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUCOSA INFLAMMATION; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0038303307     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01142-2     Document Type: Note

References (74)

1. Bayer R, Oppenheimer GM. AIDS Doctors, voices from the epidemic, an oral history. Oxford. University Press, 2002.
2. Control CfD. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 1981;30:305-08.
3. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocytis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425-31.
4. Stahl RE, Friedman-Kien A, Dubin R, et al. Immunological abnormalities in homosexual men: relationship to Kaposi's Sarcoma. Am J Med 1982; 73: 171-78.
5. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T- lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
6. Zhu T, Korber BT, Nahmias AJ, et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998; 391: 594-97.
7. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroval therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2: 487-93.
8. Cecchi RL. Health care advocacy for AIDS patients. QRB Qual Rev Bull 1986; 12: 297-303.
9. Ouelette SC, Cassel JB, Maslanka H, Wong LM. GMHC volunteers and the challenges and hopes for the second decade of AIDS. AIDS Educ Prev 1995; 7 (suppl): 64-79.
10. Maslanka H. Burnout, social support and AIDS volunteers. AIDS Care 1996; 8: 195-206.
11. James JS. More attention to HIV reporting as GMHC changes policy. Gay Mens Health Crisis. AIDS Treat New 1998 (287): 7-8.
12. Earickson RJ. International behavioral responses to a health hazard: AIDS. Soc Sci Med 1990; 31: 951-62.
13. Nattinger AB, Hoffmann RG, Howell-Pelz A, Goodwin JS. Effect of Nancy Reagan's mastectomy on choice of surgery for breast cancer by US women. JAMA 1998; 279: 762-66.
14. Nancy Reagan's choice of mastectomy seems to have influenced many breast cancer patients. Oncology (Huntingt) 1998; 12: 668.
15. Administration FaD Guidance for industry. Clinical considerations for accelerated and traditional approval of antiretroviral drugs using plasma HIV RNA measurements., 1999.
16. McKinney MM, Marconi KM. Delivery HIV services to vulnerable populations: a review of CARE act-funded research. Public Health Rep 2002; 117: 99-113.
17. Studdert DM. Charges of human immunodeficiency virus discrimination in the workplace: the Americans with Disabilities Act in action. Am J Epidemiol 2002; 156: 219-29.
18. McGrath MS, Hwang KM, Caldwell SE, et al. GLQ223: an inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte lineage. Proc Natl Acad Sci USA 1989; 86: 2844-48.
19. Rawlins M. In pursuit of quality: the National Institute for Clinical Excellence. Lancet 1999; 353: 1079-82.
20. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100.
21. DeVita VT Jr, Broder S, Fauci AS, et al. Development therapeutics and the acquired immunodeficiency syndrome. Ann Intern Med 1987; 106: 568-81.
22. Nixon R. The war against cancer. Prog Clin Biol Res 1987; 248: 3-8.
23. Sporn BM. The war on cancer. Lancet 1996; 347: 1377-81.
24. Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature 1987; 329: 351-54.
25. Miller M, Jaskolski M, Rao JK, et al. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 1989; 337: 576-79.
26. Navia MA, Fitzgerald PM, McKeever BM, et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989; 337: 615-20.
27. Arnold E, Jacobo-Molina A, Nanni RG, et al. Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. Nature 1992; 357: 85-89.
28. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-90.
29. Hammer SM. Increasing choices for HIV therapy. N Engl J Med 2002; 346: 2022-23.
30. Dove A. New class of HIV drugs shows promise. Nat Med 2001; 7: 1265.
31. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
32. Rabkin M, El-Sadr W, Katzenstein DA, et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 2002; 360: 1503-05.
33. Gonsalves G. Next steps on ART. Nat Med 2002; 8: 644.
34. Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. BMJ 2002; 325: 269-71.
35. Intermational Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-30.
36. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 225-32.
37. Pozniak A. Surrogacy in HIV-1 clinical trials. Lancet 1998; 351: 536-37.
38. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000; 92: 179-81.
39. Loeb DD, Swanstrom R, Everitt L, et al. Complete mutagenesis of the HIV-1 protease. Nature 1989; 340: 397-400.
40. Stebbing J, Gazzard BG. Clinical utility of resistance testing. J HIV ther 2002; 7: 75-80.
41. Katzenstein DA. Viral phenotype and genotype as markers in clinical trials. J Acquir Immune Defic Syndr Hum Retroviral 1995; 10 (suppl): S25-34.
42. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001; 32: 774-82.
43. Hachiya A, Aizawa-Matsuoka S, Tanaka M, et al. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5). Antimicrob Agents Chemother 2001;45:495-501.
44. Saag MS. HIV resistance testing in clinical practice: a Qaly-fied success. Ann Intern Med 2001; 134: 475-77.
45. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134: 440-50.
46. Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002; 116: 834-38.
47. Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 2002; 16: 1743-47.
48. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161: 1962-68.
49. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-61.
50. Boissel JP, Nony P. Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet 2002; 41: 1-6.
51. Hugen PW, Burger DM, Aarnoutse RE, et al. Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. Ther Drug Monit 2002; 24: 579-87.
52. Marzolini C, Buclin T, Decosterd LA, et al. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 2001; 23: 394-98.
53. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987; 5: 2017-31.
54. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002; 36: 702-06.
55. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300: 1036-45.
56. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36.
57. Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann Oncol 1997; 8: 15-25.
58. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
59. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluororacil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6: 4705-12.
60. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51: 1-52.
61. Batstra L, Bos EH, Neeleman J. Quantifying psychiatric comorbidity - lessions from chronic disease epidemiology. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 105-11.
62. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002; 324: 813.
63. Carael M, Holmes KK. Dynamics of HIV epidemics in sub-Saharan Africa: introduction. AIDS 2001; 15 (suppl): S1-4.
64. McCusker J, Stoddard AM, Hindin RN, et al. Changes in HIV risk behavior following alternative residential programs of drug abuse treatment and AIDS education. Ann Epidemiol 1996; 6: 119-25.
65. Korenromp EL, Bakker R, Vlas SJ, et al. HIV dynamics and behaviour changes as determinants of the impact of sexually transmitted disease treatment on HIV transmission in the context of the Rakai trial. AIDS 2002; 16: 2209-18.
66. Nagelkerke NJ, Jha P, de Vlas SJ, et al. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ 2002; 80: 89-96.
67. Sikkema KJ, Kelly JA, Winett RA, et al. Outcomes of a randomized community-level HIV prevention intervention for women living in 18 low-income housing developments. Am J Public Health 2000; 90: 57-63.
68. Angell M. The ethics of clinical research in the Third World. N Engl J Med 1997; 337: 847-49.
69. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodefiency virus in developing countries. N Engl J Med 1997; 337: 853-56.
70. Pitler LR, Ethics of AIDS clinical trials in developing countries: a review. Food Drug Law J 2002; 57: 133-53.
71. Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med 1997; 337: 1003-05.
72. Karnovsky DA, Burchenhall JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod MC (Ed). Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949: 199-205.
73. Gehan EA. The determination of the number of patients required in preliminary and follow-up trials of a new chemotherapy agent. J Chronic Dis 1961; 13: 346-53.
74. Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976; 1: 899-900.